Related references
Note: Only part of the references are listed.Referral patterns in advanced non-small cell lung cancer: Impact on delivery of treatment and survival in a contemporary population based cohort
Krista Noonan et al.
LUNG CANCER (2014)
Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
Eamon M. Berge et al.
CLINICAL LUNG CANCER (2013)
Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?
Adrian G. Sacher et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Real-World Effectiveness of Systemic Agents Approved for Advanced Non-Small Cell Lung Cancer: A SEER-Medicare Analysis
Taofeek K. Owonikoko et al.
ONCOLOGIST (2013)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations NEJ 003 Study
Makoto Maemondo et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Survival among non-small cell lung cancer patients with poor performance status after first line chemotherapy
Ramzi G. Salloum et al.
LUNG CANCER (2012)
Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
Elisabeth Quoix et al.
LANCET (2011)
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
Denise R. Aberle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States
Kathleen Lang et al.
LUNG CANCER (2009)
The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
Giorgio Scagliotti et al.
ONCOLOGIST (2009)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis
Andrea Ardizzoni et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Elderly patients benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer
Glen J. Weiss et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life - A randomized controlled trial
Chandra P. Belani et al.
LUNG CANCER (2006)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: Evidence from Surveillance, Epidemiology and End Results-Medicare
SA Ramsey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial
R Rosell et al.
ANNALS OF ONCOLOGY (2002)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
